当前位置:首页 > 报告详情

德勤:2021年中国生物科技园产业园报告-借力生态系统制胜(英文版)(16页).pdf

上传人: 云闲 编号:46382 2021-07-23 16页 1.43MB

1、Chinas Biotech Parks Leveraging the ecosystem for success2册子 / 报告标题 | 章节标题The status and development of BPIPs in China 2Overview of tax and financial supporting policies for 5the Chinese biopharmaceutical industry Policy considerations for biopharma companies in China 8Conclusion 10Contacts 111China

2、s Biotech Parks Leveraging an ecosystem for successIntroductionThe Chinese government has recognized the biopharmaceutical industry (BPI) as of strategic importance and been vigorously advocating its optimum development in China. Creating the necessary infrastructure for industry development has bee

3、n and remains to be one of its key objectives and ambitions. Many local governments have established special biopharmaceutical industrial parks (BPIPs) and issued policies to support and promote industry development. Market participants need to pay close attention to these developments to maximize t

4、heir chances of success in investment and management. BPI enterprises are high risk, require substantial investment and advanced technology, and have a lengthy development cycle. BPIPs have been one of the main contributors to the rapid development of the Chinese biopharmaceutical industry. Chinese

5、BPIPs have become much more developed, and are attracting a growing number of domestic and multinational biopharmaceutical enterprises. BPIPs are also the main platforms through which local governments seek to attract, foster and promote industry development. BPIPs across China are being transformed

6、 and upgraded to provide enterprises with more innovative resources and more efficient services. This paper presents the current development conditions of Chinese BPIPs, summarizes common local support policies, and discusses how biopharma enterprises can use industrial parks and related policies to

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
根据报告的内容,本文主要介绍了中国生物制药工业园区(BPIPs)的发展现状、税收和财政支持政策,以及生物制药公司在中国的策略考虑。文章指出,中国政府将生物技术和制药业视为战略重点,并积极促进其在中国的发展。中国已建立387个国家级工业园区,其中193个(49.9%)专注于制药业。2016-2019年,中国BPIPs的产值从1310亿人民币增长到2130亿人民币,年复合增长率超过17%。BPIPs处于不同的发展阶段,但地方支持政策是吸引企业的主要因素。 在税收和财政支持政策方面,国家层面提供了包括高新技术企业和先进服务业企业优惠税率、研发费用加计扣除、固定资产加速折旧、特定跨境服务增值税零税率或免税、特定企业或进口商品关税和进口增值税减免等政策。地方政府也提供了包括创新和研发鼓励、国际市场拓展、产业化、公共服务平台建设和产业发展引导基金等地方性支持政策。 对于生物制药公司而言,选择合适的BPIPs进行投资和布局,需要考虑地方政府的财政激励措施、供应链的可靠性和成熟度、公共服务能力等因素。
中国生物制药园区发展现状如何? 生物制药企业如何利用税收优惠政策? 生物制药企业如何吸引和留住人才?
客服
商务合作
小程序
服务号
折叠